| Literature DB >> 30991023 |
Inge Van Der Werf1, Catriona Jamieson2.
Abstract
A prevalent eukaryotic N6-methyladensosine (m6A) post-transcriptional mark can be "erased" by the m6A demethylase FTO, which is commonly deregulated in acute myeloid leukemia (AML). In this issue of Cancer Cell, Huang et al. design small-molecule FTO inhibitors, FB23 and FB23-2, and demonstrate their potent inhibitory impact in AML models.Entities:
Year: 2019 PMID: 30991023 DOI: 10.1016/j.ccell.2019.03.011
Source DB: PubMed Journal: Cancer Cell ISSN: 1535-6108 Impact factor: 31.743